Study Will Evaluate The Safety And Efficacy Of Anidulafungin In Patients With Candidemia Or Invasive Candidiasis
Status:
Completed
Trial end date:
2010-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to further evaluate the safety and effectiveness of intravenous
anidulafungin (Eraxis™) in patients with a diagnosis of candidemia or invasive candidiasis,
which is a fungus infection of the blood or tissue. Currently the drug is approved for
treatment using a daily dose of IV medication until 14 days after the fungus disappears from
the blood. This study will evaluate the effectiveness of intravenous anidulafungin when it is
administered for 5-28 days followed by oral antifungal medication. Study patients will be
assessed for response to treatment throughout the study drug treatment period.